TerminatedNCT00287742
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
Medication studySchizophrenia
Understand this study
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMarch 2002
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 33
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- Not clearly listed
- Official registry ID
- NCT00287742
- Official title
Show the full official title
Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
Recruitment & locations
TerminatedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including risperidone.
Is this study still recruiting?
The registry lists this study as terminated.
